Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hainan Quanxing Pharmaceutical
Hainan, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Hainan Quanxing Pharmaceutical has multiple approved generic drugs, including propacetamol hydrochloride, piperaquine phosphate, and alendronate sodium, addressing therapeutic areas such as pain, malaria, and osteoporosis. The company does not appear to have late-stage innovation assets but is active as a producer and supplier of finished formulations and active pharmaceutical ingredients.
- Therapeutic areas
- NeurologyInfectious DiseasesEndocrinology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Hainan Quanxing Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hainan Quanxing Pharmaceutical.